Position in CGON
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$14,883,340
-$6,200,535 QoQ
Shares Held
209,477
-32.8% QoQ
Ownership
0.236%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#55
of 226 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 0%
Shared 89%
None 11%
Common Shares in CGON Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026AMERIPRISE FINANCIAL INC holds $5,025,615,702 across 202 Biotechnology names. CGON ranks #47 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,604,822 | $1,293,893,227 | |
| 2 | INSM |
INSMED Inc
|
6,179,571 | $658,865,856 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
1,215,523 | $292,904,576 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
1,039,702 | $194,715,388 | |
| 5 | ARGX |
Argenx SE
|
181,464 | $168,356,853 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
227,457 | $141,828,535 | |
| 7 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
231,205 | $124,145,521 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
1,551,663 | $115,567,858 |
All Filings in CGON
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $14,883,340 | 209,477 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $21,083,875 | 311,523 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $9,984,604 | 240,477 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $4,347,057 | 107,921 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $2,871,856 | 110,456 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $471,309 | 19,245 | Shares | Defined | 2025-05-14 | |
| 2024-12-31 | $629,409 | 21,946 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $486,527 | 12,895 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $330,725 | 10,476 | Shares | Defined | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||